Cancer treatment firm Sirtex Medical and contrast agent manufacturer Guerbet are collaborating to advance research in the interventional treatment of primary and secondary metastatic liver cancer.
The objective of the collaboration is to evaluate the unmet clinical treatment needs in patients with hepatocellular carcinoma, metastatic colorectal cancer, neuroendocrine tumors, and a range of other secondary liver cancers, the companies said.
The exact scope of the collaboration and development activities between Sirtex and Guerbet is being finalized, with additional announcements expected to be made later this year.
